INR ranges, DOACs and heparin in cardiac-vascular care
An INR is a ratio, not a dose, and the range it aims at depends on why the patient takes warfarin. This page starts with that arithmetic and the ranges, then moves through warfarin starts, the direct oral anticoagulants, the heparins, heparin-induced thrombocytopenia and the venous clots these drugs treat.
Weight of each domain in the 125 scored items; filled squares mark where this topic draws from
IAssessment and Diagnosis22 %
IIPlanning and Implementation (this topic draws on it)35 %
IIIEvaluation and Modification (this topic draws on it)18 %
IVPatient and Community Education (this topic draws on it)25 %
A patient with a mechanical mitral valve takes warfarin and is scheduled for elective hip replacement. The cardiac-vascular nurse anticipates that the perioperative plan will include:
Choose an option; the reasons for all four open together.
A mechanical mitral valve carries a high clot risk, so heparin covers the days when warfarin is held and the INR is below range.
Major orthopedic surgery is not done at a fully therapeutic INR.
Going without a bridge is reserved for lower-risk valves such as a bileaflet aortic valve without other risk factors.
DOACs are not used with mechanical heart valves.
Show the key without choosing
Weight of each domain in the 125 scored items; filled squares mark where this topic draws from
IAssessment and Diagnosis22 %
IIPlanning and Implementation (this topic draws on it)35 %
IIIEvaluation and Modification (this topic draws on it)18 %
IVPatient and Community Education (this topic draws on it)25 %
16 anticoagulation and VTE questions
Four answer choices per item; pick the best one.
Tally: 0 right, 0 tried, 16 in this set
Item 2 / 16 · Anticoagulation
Which postoperative cardiac surgery patient should receive mechanical rather than pharmacologic VTE prophylaxis?
Older age raises clot risk; it favors drug prophylaxis rather than excluding it.
A past DVT is one of the strongest reasons to use drug prophylaxis.
Active bleeding rules out anticoagulant prophylaxis, so compression devices are used instead.
Obesity is a VTE risk factor and no reason to avoid anticoagulant prophylaxis.
Show the key without choosing
Item 3 / 16 · Anticoagulation
A patient receiving a continuous IV unfractionated heparin infusion for deep vein thrombosis is on a weight-based titration protocol. Which result does the cardiac-vascular nurse use to adjust the infusion rate?
Platelets are watched for heparin-induced thrombocytopenia but do not set the infusion rate.
Unfractionated heparin infusions are adjusted to the aPTT, or an anti-Xa level, according to the protocol.
Hemoglobin screens for bleeding but is not used to titrate the dose.
The INR tracks warfarin, not heparin.
Show the key without choosing
Item 4 / 16 · Anticoagulation
A patient with a mechanical mitral valve has an INR of 1.8, below the prescribed range, after a week of eating large amounts of kale. Which new finding should the cardiac-vascular nurse report as possible valve thrombosis?
A soft flow murmur across a prosthetic valve is common and expected.
A loud, crisp click is how a working mechanical valve normally sounds.
Bruising points to too much anticoagulation, the opposite of this problem.
Clot on the leaflets restricts their motion, so the normally crisp click becomes muffled or disappears.
Show the key without choosing
Item 5 / 16 · Anticoagulation
A patient who takes warfarin every evening at 5 PM realizes at 9 AM that yesterday's dose was missed. The cardiac-vascular nurse instructs the patient to:
Two doses in one day, even spaced apart, can push the INR into the bleeding range.
Doubling up is the classic catch-up error that overshoots the INR.
A warfarin dose remembered the next day is skipped; the usual dose is taken on time and the miss is noted for the anticoagulation clinic.
Stopping leaves the patient unprotected for days over a single missed dose.
Show the key without choosing
Item 6 / 16 · Anticoagulation
A 72-year-old patient taking apixaban for atrial fibrillation reports black, tarry stools for 2 days. Hemoglobin has fallen from 12.8 to 11.3 g/dL; BP is 118/70 mm Hg and heart rate is 96/min. The cardiac-vascular nurse's initial action is to:
The INR does not measure apixaban's effect, so waiting for it delays action on a real bleed.
A day without the drug carries far less risk than ongoing GI bleeding.
Vitamin K reverses warfarin, not factor Xa inhibitors.
Black stools with a 1.5 g/dL hemoglobin drop and a heart rate of 96/min are a significant bleed, so the next dose is held while the provider is told.
Show the key without choosing
Item 7 / 16 · Anticoagulation
During an alteplase infusion for massive pulmonary embolism, the cardiac-vascular nurse notes oozing of blood around a peripheral IV site. Vital signs and neurologic status are unchanged from baseline. The nurse's most appropriate action is to:
The infusion is stopped for major bleeding, such as a neurologic change or hemodynamic instability, neither of which is present.
Protamine has no effect on a fibrinolytic such as alteplase, so it would not stop the oozing.
Superficial oozing at puncture sites is expected during a fibrinolytic and is handled with pressure while the infusion continues.
New punctures during lysis create another bleeding site.
Show the key without choosing
Item 8 / 16 · Anticoagulation
A patient with limited literacy takes warfarin in doses that vary by day of the week. Which strategy best prevents dosing errors?
A milligram list requires reading and converting to tablets, the very skills that are limited.
Spoken instructions given weeks apart are easily forgotten between visits.
A calendar showing the actual tablets for each day does not depend on reading or arithmetic.
Routinely splitting tablets adds calculation steps and new chances for error.
Show the key without choosing
Item 9 / 16 · Anticoagulation
During a home visit, the cardiac-vascular nurse finds a bottle labeled "Coumadin" and another labeled "warfarin," and the patient has been taking a tablet from each. The nurse's best response is:
A second bottle at home is how the double dosing started.
Alternating still keeps two supplies and invites the same mix-up; one supply is kept.
They are the same drug, so taking both simply doubles the anticoagulant.
Coumadin is a brand name for warfarin, so taking both doubles the dose; the INR is checked and the prescriber told.
Show the key without choosing
Item 10 / 16 · Anticoagulation
A patient develops a proximal DVT 10 days after hip replacement surgery and starts rivaroxaban. The patient asks how long the anticoagulant will be needed. The cardiac-vascular nurse explains that treatment usually lasts:
A clot provoked by a major temporary risk such as surgery is treated for 3 months and then usually stopped.
Six weeks is shorter than the standard treatment phase for a proximal DVT.
Swelling can settle long before treatment is complete, so it does not set the duration.
Extended treatment is weighed for unprovoked or recurrent clots, not for one clearly provoked by surgery.
Show the key without choosing
Item 11 / 16 · Anticoagulation
Eight months after a proximal DVT, a patient reports aching and heaviness of that leg with swelling that worsens by evening and eases with elevation. The skin near the ankle is brownish. The cardiac-vascular nurse recognizes:
Arterial disease causes pain on walking that worsens with elevation, the opposite of this pattern.
A new clot usually brings sudden, persistent swelling and pain rather than a months-long daily pattern that eases overnight.
Lymphedema is firm, does not ease much with elevation and does not cause brown ankle skin.
Months after a DVT, damaged valves leave the leg aching, heavy and swollen by evening, easing with elevation, often with brownish skin near the ankle.
Show the key without choosing
Item 12 / 16 · Anticoagulation
A patient starting warfarin asks about drinking alcohol. Which statement shows the patient understands the teaching?
Regular heavier drinking destabilizes the INR and adds bleeding risk.
Using alcohol to steer the INR, or saving it for weekends, is unpredictable and unsafe.
A binge can push the INR up sharply and heavy drinking makes it unstable, so alcohol stays occasional and limited.
Alcohol changes how warfarin is handled, so ignoring it leads to INR swings.
Show the key without choosing
Item 13 / 16 · Anticoagulation
A patient is switching from warfarin to apixaban and asks when to take the first apixaban tablet. The cardiac-vascular nurse explains that apixaban is started:
A week without coverage leaves the patient unprotected against stroke.
Starting while warfarin is still fully active stacks two anticoagulants and raises bleeding risk.
Overlapping two drugs is how warfarin itself is started, not how a switch to apixaban works.
Warfarin is stopped first and apixaban begins when the INR drops below 2.0, so the two do not overlap.
Show the key without choosing
Item 14 / 16 · Anticoagulation
A patient finishing treatment for a DVT plans a 6-hour flight. Which advice should the cardiac-vascular nurse give?
Drinking less leads to dehydration, which thickens the blood; restroom trips are also useful walks.
Moving and working the calf muscles during a long flight keeps venous blood flowing and lowers clot risk.
Hours of sitting still is the stasis that raises clot risk on long trips.
Extra doses add bleeding risk without a proven benefit; the usual schedule continues.
Show the key without choosing
Item 15 / 16 · Anticoagulation
A 34-year-old woman taking rivaroxaban for a DVT diagnosed 6 weeks ago reports that her periods are much heavier, soaking a pad every 1 to 2 hours. The cardiac-vascular nurse should:
Soaking a pad every 1 to 2 hours can lead to iron deficiency and anemia, so it is not dismissed.
Heavier periods are common on oral anticoagulants; the provider can treat the bleeding or adjust the regimen, while the drug keeps protecting against a new clot.
Stopping on her own during the first months of treatment leaves her exposed to clot extension or recurrence.
Diet alone does not address bleeding this heavy, and waiting delays treatment.
Show the key without choosing
Item 16 / 16 · Anticoagulation
Eight days after a total knee replacement, a patient discharged on apixaban 2.5 mg twice daily for 12 days is walking well with a walker and asks whether the pills can stop now. The cardiac-vascular nurse explains that:
Clot risk after joint replacement continues in a patient who is up and walking, which is why the labeled apixaban course after knee replacement runs 12 days.
A healed incision says nothing about clot risk in the leg veins.
Being up and walking lowers the risk but does not remove it; feeling mobile is the usual reason prophylaxis gets cut short.
Tying the course to the walker swaps the prescribed duration for a mobility milestone, so it may stop too early or run on without an order.
Show the key without choosing
–/16
Your tally for this page
Kept in this tab alone: closing or refreshing the tab wipes it.
The prothrombin time depends on the thromboplastin reagent a laboratory uses, so the same blood can give different times in different labs. The international normalized ratio corrects for that: the patient's PT is divided by the lab's mean normal PT, and the ratio is raised to the power of the reagent's international sensitivity index (ISI).
The formula, worked for one sample with a patient PT of 26 seconds and a laboratory mean normal PT of 12 seconds:
PT ratio
26 s ÷ 12 s
2.17
Apply the reagent's ISI of 1.0
2.17 to the power 1.0
2.17
INR
rounded
2.2
With an ISI other than 1.0, the same ratio gives a different INR.
INR target ranges by indication
For atrial fibrillation and venous thromboembolism the target is an INR of 2.0 to 3.0, aiming at 2.5; valves differ:
The chart should show the indication and the target together. A result of 2.3 is on target for one patient and below it for another. Valve surgery and recovery are covered on cardiac surgery.
Starting warfarin and keeping it in range
Warfarin blocks the vitamin K cycle that the liver needs to make four clotting factors: prothrombin (factor II) and factors VII, IX and X. Factor VII falls first and moves the INR within days, but prothrombin has the longest half-life, so the full antithrombotic effect takes longer than the INR suggests. For acute VTE the 2012 CHEST guideline therefore overlaps warfarin with a parenteral anticoagulant for a minimum of 5 days, stopping the injection only once the INR has stayed at 2.0 or above for 24 hours or more.
Once a patient is stable, the measure of control is the share of time the INR spends inside its range, often reported by clinics as time in therapeutic range.
Home INR testing and the anticoagulation clinic
Both appear in the CV-BC outline by name: point-of-care testing under IV.B.2 outpatient monitoring, and the anticoagulation clinic under IV.A.5 community resources, in Patient and Community Education.
The ASH 2018 guideline on optimal management of anticoagulation therapy (2018) makes a strong recommendation for patient self-management, with home point-of-care INR testing, in patients able to do it, and a conditional one for care by a specialized anticoagulation management service rather than routine primary care. A clinic of that kind runs on protocols: the nurse or pharmacist reviews each result, adjusts the dose within the protocol, sets the next test date and records each contact. Training for self-testing covers the fingerstick technique, the meter's quality checks and when a result is phoned in.
Direct oral anticoagulants at the bedside
Four DOACs are marketed in the US: dabigatran, a direct thrombin inhibitor, and the factor Xa inhibitors apixaban, rivaroxaban and edoxaban. Their doses depend on the indication, kidney function and, for some, age and weight, so a current creatinine clearance belongs in the chart before the first dose and at intervals after.
The prescribing information adds handling rules that are easy to miss:
Dabigatran capsules are swallowed whole, because breaking, chewing or emptying one increases exposure, and they stay in the original package away from moisture (Pradaxa prescribing information, 2025).
Rivaroxaban at its treatment strengths is taken with food, and for atrial fibrillation with the evening meal (Xarelto prescribing information, 2026).
Edoxaban carries a boxed warning of reduced efficacy in nonvalvular atrial fibrillation when creatinine clearance is above 95 mL/min (Savaysa prescribing information, 2025).
The choice to anticoagulate a patient with atrial fibrillation, and which drug to prefer, is on atrial fibrillation.
Unfractionated and low-molecular-weight heparin
Unfractionated heparin acts within minutes IV and is cleared quickly, which makes it the drug for the cath lab, the early hours of an acute coronary syndrome and patients who may need an urgent procedure. It runs by a weight-based nomogram, and pump programming and bag changes follow the unit's independent double-check policy.
Enoxaparin, a low-molecular-weight heparin, is given subcutaneously by weight. The ASH 2018 guideline suggests dosing it on actual body weight. A boxed warning in the Lovenox prescribing information (2026) covers spinal or epidural hematoma when neuraxial anesthesia or a spinal puncture is involved, so catheter timing is coordinated with anesthesia. The same document asks that the air bubble in the prefilled syringe be left in place, that sites alternate between the left and right sides of the abdominal wall, and that the site not be rubbed afterward, which adds bruising. Dose reduction for severe kidney impairment follows the prescribing information and the order.
Heparin-induced thrombocytopenia
HIT is an immune reaction: antibodies against complexes of heparin and platelet factor 4 activate platelets, so the count falls while the risk of arterial and venous clots rises. The danger is clotting more than bleeding.
Thrombocytopenia: how far the platelet count has fallen;
Timing of the fall after heparin exposure;
Thrombosis or other sequelae;
oTher causes of a low count.
With a low-probability score, ASH recommends against both laboratory testing for HIT and empiric treatment. With an intermediate or high score, every source of heparin stops, including flushes, heparin-coated catheters and LMWH, and the prescriber switches to a non-heparin anticoagulant: argatroban, bivalirudin, fondaparinux or a DOAC, chosen by the prescriber for the patient's kidney and liver function and bleeding risk. ASH advises against starting a vitamin K antagonist until the platelet count recovers, because venous limb gangrene can follow.
About 1.0. The ratio compares the patient's prothrombin time with the laboratory's mean normal, so a person with normal clotting sits near 1.0; each laboratory publishes its own reference range.